Grants for State governments - Health

The National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for the TrialNet Clinical Network Hub (HUB). The purpose of this Notice of Funding Opportunity (NOFO) is to continue support for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit for clinical trials focusing on the prevention of and early intervention in type 1 diabetes (T1D). The main objective of the HUB is to increase the efficiency and productivity of the TrialNet network by providing coordination of communications and outreach and developing new tools and approaches to increase screening, recruitment and retention. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. This NOFO will utilize the U01 activity code. Details of the planned NOFO are provided below.

CDC announces the availability of approximately $7 million in competitive supplemental funding for the 32 health department jurisdictions currently receiving Ending the HIV Epidemic in the US (EHE) initiative funding resources under notice of funding opportunity (NOFO) PS24-0047: High-Impact HIV Prevention and Surveillance Programs for Health Departments. Fully aligned with PS24-0047, the supplemental NOFO prioritizes acceleration of progress toward achieving the national HIV prevention goal of 50% pre-exposure prophylaxis (PrEP) coverage by the end of 2025. Jurisdictions with greater need for PrEP and lower uptake among priority populations disproportionately affected by HIV and low PrEP prescriptions (i.e., Black and Latino gay, bisexual, and other men who have sex with men (MSM), and Black cisgender and transgender women) need these additional resources and flexibility to accelerate PrEP uptake through patient navigation/case management services and improve access to and utilization of existing PrEP services not covered by other financial resources. Recipients will implement enhanced and expanded programmatic activities to increase access to and uptake of PrEP for priority populations and to help further eliminate structural and social barriers that prevent equitable access to PrEP within EHE jurisdictions. Additionally, these enhanced and expanded PrEP programs will incorporate elements to increase HIV non-occupational post-exposure prophylaxis (PEP) and doxycycline post-exposure prophylaxis (doxy PEP) awareness and access, including activities with clinicians, non-clinical community-based organizations (CBOs), and persons at risk for HIV acquisition.The supplemental NOFO's period of performance is September 30, 2024 - May 31, 2025 (8 months). Recipients may request to continue implementation of supplemental programmatic activities during PS24-0047 Budget Year 2 (June 1, 2025 - May 31, 2026). Recipients will implement concurrently all required programmatic activities as described in both PS24-0047 and the forthcoming supplemental NOFO.

This grant provides funding to support diverse postdoctoral researchers in transitioning to independent faculty positions while conducting innovative research on pain and substance use disorders.

The purpose of this notice of funding opportunity (NOFO) is to support investigators who will form large, electronically-generated cohorts in Latin America of HIV-negative men who have sex with men (MSM), transgender women (TGW), people who inject drugs (PWID), and/or female sex-workers and follow them to study the epidemiology of HIV incidence. Continued follow-up of those persons who acquire HIV will be required to study the epidemiology of viral suppression. Comparisons of participants by seroconverstion status will provide information on geographic and socially defined areas of high HIV incidence as well as on both personal and structural vulnerabilities to HIV infection. Among participants who seroconvert, comparisons of those becoming rapidly engaged in care and who reach non-detectable HIV levels to those whose virus remains detectable will inform on the treatment of HIV in Latin American countries. This NOFO will allow digital trials to determine optimal study approaches, or to pilot evidence-based digital (mHealth and online) HIV prevention and treatment interventions to both reduce HIV incidence and improve treatment in the most vulnerable populations.Letter of Intent Due Date(s) 30 days prior to the application due date

This funding opportunity supports researchers conducting early-stage clinical trials for neurological disorders, focusing on innovative treatments and therapies that could lead to future efficacy studies.

This funding opportunity provides financial support to non-profit and public organizations that deliver essential primary health care services to underserved communities, ensuring access regardless of patients' ability to pay.

This funding opportunity provides financial support to organizations in Sierra Leone to develop and implement community-led monitoring systems that improve the quality and accessibility of HIV services for key populations.

The Heartland Healthy Living Fund is a grant initiative designed to improve public health in Ellis, Rooks, and Trego Counties, Kansas. Established by the Kansas Health Foundation, this fund is part of the Giving Resources to our World (GROW II) match grant challenge. It aims to support programs and projects that promote healthy living by encouraging healthy lifestyles, behaviors, and environments. Grants will focus on preventative measures rather than healthcare services or support for existing illnesses. Grant renewed every year. Grant Fall annual opening/ closing deadline: September 15th to November 15th

This funding opportunity supports community-based projects that enhance access to preventive health services for underserved children, focusing on behavioral health, immunizations, and well-visits.

This funding opportunity supports researchers developing and testing behavioral interventions for drug abuse treatment, including those addressing comorbidities and utilizing technology to improve outcomes.

This funding opportunity supports the development and testing of cancer-related interventions through real-world clinical trials, particularly targeting diverse populations and addressing health disparities in the United States.

This funding opportunity supports U.S. institutions conducting research to improve health and performance for astronauts during human space exploration missions.

This funding opportunity supports collaborative clinical studies on mental illness across multiple research sites, encouraging diverse participation and innovative research into genetics, biomarkers, and treatment responses.

This Notice of Intent to Publish is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects for the following Notice of Funding Opportunity (NOFO), which is expected to be published in January 2024, with an anticipatedapplication receipt date in May 2024. The Brain Research through Advancing Innovative Neurotechnologies(BRAIN) Initiative intends to promote a new initiative by publishing a NOFO to solicit applications that would support development and preclinical testing, beginning withproof of concept,of next-generation recording and/or modulation devices for human use to further our understanding of the human central nervous system and treat nervous system disorders. This NOFO will utilize the R18 activity code. Details of the planned NOFO are provided below.

This funding opportunity provides financial support to organizations that aim to improve services for older adults with behavioral health issues in senior nutrition programs, focusing on creating accessible and culturally sensitive practices.

This funding opportunity invites researchers to develop and apply advanced imaging techniques to better understand the role of inflammation in cancer, fostering collaboration between cancer scientists and imaging experts.

This funding opportunity supports research training for underrepresented students and health professionals in cardiovascular, pulmonary, hematologic diseases, and sleep disorders, aiming to increase diversity in the biomedical research workforce and reduce health disparities.

This Funding Opportunity Announcement (FOA) allows for renewal and competitive revision applications, and their resubmissions, for funded U24?Research Resource/Infrastructure?applications?that?support?large-scale, complex research programs focused on?Alzheimers disease (AD) and?Alzheimers disease-related dementias (ADRD).?It is anticipated that such programs will likely involve a team of investigators within a single institution or a consortium of?institutions?and?align with one or more?AD/ADRD implementation research milestones?supporting the?research goals of the??National Plan to Address Alzheimers and Related Dementias.

The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorder (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotypes and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications may examine any type of variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. NIDA expects these studies to uncover novel mechanisms that contribute to SUD and facilitate the discovery of targets for intervention and guide the development of individualized therapeutics to treat these different aspects of SUD.

This funding opportunity provides financial support for research and evaluation projects aimed at improving malaria control and prevention strategies in Kenya, specifically targeting collaborations with local health institutions.